EGFR inhibitors suppress house dust mite allergen Der pII induced inflammation in monocytes and macrophages

Read full text
Authors: Ya-Hui Chiang, I‐Lun Hsin, Ping-Ju Chen, Hui-Yi Chang, Jiunn-Liang Ko, Ko Huang Lue, Yu-Fan Liu
Cited by: 1
References: 25

Abstract

Introduction: Allergic asthma, often triggered by house dust mites (HDMs), is characterized by airway inflammation, mucus hypersecretion, and airway hyperresponsiveness. Among the major HDM allergens, Der pII plays a significant role in promoting inflammation. This study investigates the role of epidermal growth factor receptor (EGFR) inhibitors in modulating Der pII-induced cytokine production and inflammation in human immune cells. Methods: Recombinant GST-Der pII protein was expressed and purified for subsequent studies. Human peripheral blood mononuclear cells (HPBMC), THP-1 monocytes, THP-1-derived macrophages, and pulmonary alveolar macrophages (NR8383) were exposed to Der pII, followed by treatment with EGFR inhibitors AZD-9291 and Tarceva. Enzyme-linked immunosorbent assay (ELISA) was used to detect the expressions of IL-6 and IL-8. Nitric oxide (NO) levels were determined using the Griess Reagent System. Results: Der pII significantly induced pro-inflammatory cytokines, including IL-6, IL-8, and TNF-α in HPBMC and THP-1 cells. Both EGFR inhibitors reduced the secretion of IL-6 and IL-8 in these cell types. In THP-1 macrophages, AZD-9291 suppressed IL-6 expression and CD14/CD36 macrophage markers. Moreover, AZD-9291 significantly inhibited NO production in alveolar macrophages. Conclusions: These findings suggest that EGFR plays a critical role in mediating Der pII-induced inflammation, and EGFR inhibitors may represent a potential therapeutic approach for controlling HDM-induced allergic inflammation.

Fields of Study & Subjects

Asthma and respiratory diseases Allergic Rhinitis and Sensitization Psoriasis: Treatment and Pathogenesis

Publication details

Journal / source
Frontiers in Allergy
Publisher
Frontiers Media SA
Volume
7
Pages
1748679–1748679
Publication date
6 February 2026
Language
EN